Abigail Brooks, MA

The 9-week intervention targeting positive psychological wellbeing in IBS was feasible, well-accepted, and linked to improvements in IBS-related outcomes.

Any alcohol intake was linked to a greater risk of liver mortality, but healthy diet and physical activity lowered this risk across all drinking patterns.

The REMS label update reduces the frequency of liver function monitoring and removes the embryo-fetal toxicity monitoring requirement.

A trio of experts reflect on unmet needs in gastroparesis, from diagnosis to treatment, and discuss advances that could shape the future of care.

People with PBC and pruritus had a greater negative impact on HRQoL and reduced activity compared to those without pruritus, infrequently using medication.

Orforglipron met the primary and all key secondary endpoints in patients with obesity/overweight and type 2 diabetes, supporting global regulatory submissions.

The cross-sectional analysis of NHANES data highlights obesity and overweight’s influence on the development of obesity-related conditions in US youth.

Targeted C.difficile screening and prophylaxis focused on high-risk immunocompromised patients was linked to reductions in hospital-onset infection.

Healthcare costs and resource utilization were significantly greater in individuals with ASCVD and CKD with systemic inflammation versus those without.

Semaglutide 2.4 mg use was linked to lower medical costs and inpatient resource utilization among patients with overweight or obesity and heart failure.

Hydroxychloroquine reduced proteinuria levels with an acceptable safety profile but had limited effects on overall eGFR in primary glomerular diseases.

ACHIEVE trial data showed spironolactone 25 mg did not reduce cardiovascular mortality and hospitalization due to heart failure in dialysis patients.

The accelerated approval is based on findings from Part 1 of the ESSENCE trial and indicates the agent for noncirrhotic MASH with moderate to advanced fibrosis.

Stone clearance was similar with ureteroscopy vs shockwave lithotripsy, but the latter was associated with better recovery and patient-reported outcomes.

Findings highlight an association between psoriasis and risks of all-cause, cardiovascular, infection-related, and suicide mortality.

Providing nurses and MAs with an educational video on standardized hair loss photo techniques increased the quantity and quality of documented pictures.

The global burden of CKD attributable to high BMI has shown a consistent upward trend from 1990 to 2021, with projections further increases by 2050.

The FDA approved generic versions of Venofer (iron sucrose) injection from Viatris Inc and Amphastar Pharmaceuticals.

C difficile carriers had greater baseline hazard for hospital-onset infection than non-carriers, with risk not significantly affected by antibiotic exposure.

Findings from the IBS in America Survey suggest IBS symptoms disrupt patients’ productivity and personal activities 19 days each month.

Co-locating ID screening in an inpatient SUD program resulted in timely identification of and linkage to care for viral hepatitis and latent tuberculosis.

The once-daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and demonstrated improvements in cardiovascular risk factors.

Check out the latest renal regulatory news, clinical trial data, and nephrology research in this July 2025 recap.

Recent FDA approvals of pegcetacoplan and iptacopan revolutionize C3 glomerulopathy treatment, offering hope and targeted options for patients.

Check out expert perspectives and new research on hepatitis C, cirrhosis, and more in this July 2025 recap.

This FDA News Month in Review provides a round-up of regulatory decisions from July 2025.

From clinical trial updates in IBD to novel research about IBS and other disorders of gut brain interaction, catch up on the latest headlines in GI.

Inclisiran can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in hypercholesterolemia.

Findings confirm a significant post-pandemic rise in disorders of gut-brain interaction, including IBS and functional dyspepsia.

Tirzepatide was non-inferior to dulaglutide with an 8% lower rate of MACE-3 events while delivering greater reductions in A1C and weight.